common practice patient complains seeing improvement antidepressants clinician increase dose whatever patient taking theory everyone metabolism slightly different may therapeutic dose one person may strong enough someone else scientific basis upping dose antidepressants however since almost antidepressants flat dose response curve clinician playing around doses dealing someone read literature literature says dose matter patricia berney unit de psychopharmacologie clinique pitaux universitaires de gen ch ne bourg switzerland literature survey antidepressants doses published dialogues clinical neuroscience sep conclusion results show flat dose response curve class phenomenon selective serotonin reuptake inhibitors ssris according randomized controlled fixed dose clinical trials worth pulling quotations directly analysis literature celexa found short term studies citalopram show significant differences using change hamd madrs total score citalopram mg day different placebo lexapro found fixed dose response study escitalopram indicates mg day equally effective mg day prozac studies fluoxetine show significant differences terms clinical efficacy across dose range mg day therefore majority patients advantage increasing dose fluoxetine mg day might even case higher dose mg day less effective major depressive disorder also study dornseif et al performed years ago great importance demonstrated advantage tripling dose fluoxetine mg day outpatients fail initially respond mg day weeks next weeks patients groups responded extent rate luvox significant differences seen fluvoxamine mg day placebo paxil publication dunner dunbar table i short description study involving patients paroxetine mg day dose effective placebo even hamd depressed mood item authors reported also pooled analysis worldwide database involving patients remained fixed dose paroxetine placebo least weeks showed differences terms clinical efficacy across dose range mg day paroxetine therefore majority patients advantage increasing dose paroxetine mg day zoloft ssri sertraline show significant differences terms clinical efficacy across dose range mg day according major study fabre putman table i therefore majority patients advantage increase dose sertraline mg day tetracyclic antidepressant maprotiline otherwise known deprilept ludiomil psymion versus paxil study benkert et al used protocol dornseif et al schweizer et al evaluated two antidepressants paroxetine maprotiline study could demonstrate advantage doubling dose paroxetine mg day patients failed respond initially mg day weeks another group patients included table iv advantage increasing dosage maprotiline mg day patients failed respond initially mg day weeks could demonstrated significant benefits dose escalation found savella dalcipran toledomin ssri milnacipran commonly prescribed fibromyalgia study guelfi et al milnacipran prescribed doses mg day third group receiving fluoxetine mg day end weeks differences three groups change hamd items madrs total scores ittlocf ultimately berney said review eight clinical trials fixed doses evaluated dose response relationship ssris treatment major depressive disorders suggests dose response curve flat moreover three augmentation studies could demonstrate advantage doubling dose paroxetine tripling dose fluoxetine patients failed respond initially mg day weeks table iv heterogeneity results studies show significant difference active substance placebo highest dosage placebo read berney report carefully mentions number side effects dose response relationships indeed noted thus drugs primary clinical effect relief depression shows dose response curve whereas side effects show dose response curve lack dose response relationship course typical placebos berney results consistent separate meta analysis baker et al evidence ssri dose response treating major depression reassessed depression anxiety also conclusion reached yet another meta analysis hansen et al med decision making january february said hansen group dose statistically significant predictor categorical ham response among comparative trials nonequivalent doses trends favored higher dose categories generally statistically significant results consistent hypothesis antidepressants types listed fact basically nothing fancy placebos many antidepressants fail perform better placebo efficacy testing like placebo discernible dose response curve clinician playing around doses wasting time placebo placebo placebo dose matter i writing bullshit word book mental illness please add name mailing list notified book ready learn get free sample chapters please pass information anyone know may benefit thanks